Cargando…

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer

Cancer is one of the lethal diseases that arise due to the molecular alterations in the cell. One of those alterations associated with cancer corresponds to differential expression of Farnesoid X receptor (FXR), a nuclear receptor regulating bile, cholesterol homeostasis, lipid, and glucose metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girisa, Sosmitha, Henamayee, Sahu, Parama, Dey, Rana, Varsha, Dutta, Uma, Kunnumakkara, Ajaikumar B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607382/ https://www.ncbi.nlm.nih.gov/pubmed/35006466 http://dx.doi.org/10.1186/s43556-021-00035-2

Ejemplares similares

Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
por: Girisa, Sosmitha, et al.
Publicado: (2020)

COVID-19, cytokines, inflammation, and spices: How are they related?
por: Kunnumakkara, Ajaikumar B., et al.
Publicado: (2021)

Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer
por: Rana, Varsha, et al.
Publicado: (2021)

The promising potential of piperlongumine as an emerging therapeutics for cancer
por: Parama, Dey, et al.
Publicado: (2021)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
por: Harsha, Choudhary, et al.
Publicado: (2020)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Resveratrol Modulates Chemosensitisation to 5-FU via β1-Integrin/HIF-1α Axis in CRC Tumor Microenvironment
por: Brockmueller, Aranka, et al.
Publicado: (2023)

Calebin A targets the HIF-1α/NF-κB pathway to suppress colorectal cancer cell migration
por: Brockmueller, Aranka, et al.
Publicado: (2023)

Targeting Autophagy Using Long Non-Coding RNAs (LncRNAs): New Landscapes in the Arena of Cancer Therapeutics
por: Kumar, Aviral, et al.
Publicado: (2023)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
por: Hegde, Mangala, et al.
Publicado: (2023)

Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)
por: Pierre, Joseph F., et al.
Publicado: (2019)

Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases
por: Daimary, Uzini Devi, et al.
Publicado: (2020)

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity
por: Anderson, Kemp M., et al.
Publicado: (2021)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
por: Gangwar, Shailendra Kumar, et al.
Publicado: (2022)

Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer
por: Jayaprakash, Sujitha, et al.
Publicado: (2022)

Sorcin a Potential Molecular Target for Cancer Therapy
por: Shabnam, Bano, et al.
Publicado: (2018)

Helicobacter hepaticus Infection Promotes Hepatitis and Preneoplastic Foci in Farnesoid X Receptor (FXR) Deficient Mice
por: Swennes, Alton G., et al.
Publicado: (2014)

Loss of Farnesoid X receptor (FXR) accelerates dysregulated glucose and renal injury in db/db mice
por: Qiu, Yuxiang, et al.
Publicado: (2023)

Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer
por: Jayaprakash, Sujitha, et al.
Publicado: (2022)

Potential of Zerumbone as an Anti-Cancer Agent
por: Girisa, Sosmitha, et al.
Publicado: (2019)

Corrigendum to: “Farnesoid X receptor (FXR): Structures and ligands” [Comput. Struct. Biotechnol. J. 19 (2021) 2148–2159]
por: Jiang, Longying, et al.
Publicado: (2022)

Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties
por: Henamayee, Sahu, et al.
Publicado: (2020)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
por: Finamore, Claudia, et al.
Publicado: (2023)

Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases
por: Sajeev, Anjana, et al.
Publicado: (2022)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
por: Younis, Islam, et al.
Publicado: (2023)

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022)

FBXW7 in Cancer: What Has Been Unraveled Thus Far?
por: Sailo, Bethsebie Lalduhsaki, et al.
Publicado: (2019)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
por: Kim, Sun-Gi, et al.
Publicado: (2016)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhvvv3bil9d7r329v3hseqr6pp